These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17650450)

  • 1. Rituximab and dose dense chemotherapy in primary breast lymphoma.
    Avilés A; Castañeda C; Neri N; Cleto S; Nambo MJ
    Haematologica; 2007 Aug; 92(8):1147-8. PubMed ID: 17650450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab and dose-dense chemotherapy in primary testicular lymphoma.
    Avilés A; Nambo MJ; Cleto S; Neri N; Huerta-Guzmán J
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):386-9. PubMed ID: 19858059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast lymphoma.
    Avilés A
    Ann Oncol; 2008 Jul; 19(7):1360. PubMed ID: 18579558
    [No Abstract]   [Full Text] [Related]  

  • 4. A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
    Hertzberg M; Matthews JP; Stone JM; Dubosq MC; Grigg A; Ellis D; Benson W; Browett P; Horvath N; Januszewicz H; Abdi E; Green M; Bonaventura A; Marlton P; Cannell P; Wolf M;
    Am J Hematol; 2014 May; 89(5):536-41. PubMed ID: 24481640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
    Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment strategies in elderly patients with aggressive histology lymphoma.
    Kouroukis CT; Meyer RM
    Ann Hematol; 2001; 80 Suppl 3():B86-8. PubMed ID: 11757717
    [No Abstract]   [Full Text] [Related]  

  • 7. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
    Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
    Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma.
    Avilés A; Nambo MJ; Neri N; Cleto S; Castañeda C; Huerta-Guzmàn J; Murillo E; Contreras M; Talavera A; González M
    Med Oncol; 2007; 24(1):85-9. PubMed ID: 17673816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
    Cabanillas F; Cotto M; Liboy I; Rivera E; Pavia OA; Bruno M
    Leuk Lymphoma; 2012 Oct; 53(10):1929-33. PubMed ID: 22448918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.
    Levitt MJ; Gharibo M; Strair R; Schaar D; Rubin A; Bertino JR
    J Chemother; 2009 Aug; 21(4):434-8. PubMed ID: 19622463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Fisher RI
    Leuk Lymphoma; 2005 Nov; 46(11):1569-73. PubMed ID: 16236611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
    Kim JG; Sohn SK; Kim DH; Baek JH; Park TI; Lee KB
    J Korean Med Sci; 2004 Dec; 19(6):820-5. PubMed ID: 15608392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in the treatment of aggressive non-Hodgkin lymphoma.
    Michallet AS; Coiffier B
    Blood Rev; 2009 Jan; 23(1):11-23. PubMed ID: 18620786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma.
    Tomita N; Kodama F; Oshima R; Hashimoto C; Koharazawa H; Takemura S; Yamazaki E; Fujimaki K; Sakai R; Fujita H; Fujisawa S; Kanamori H; Motomura S; Ishigatsubo Y
    Leuk Lymphoma; 2006 Jun; 47(6):1041-7. PubMed ID: 16840195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL.
    Schmits R; Glass B; Trümper L; Pfreundschuh M;
    Ann Hematol; 2001; 80 Suppl 3():B77-83. PubMed ID: 11757714
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group.
    Economopoulos T; Psyrri A; Dimopoulos MA; Kalogera-Fountzila A; Pavlidis N; Tsatalas C; Nikolaides C; Mellou S; Xiros N; Fountzilas G
    Cancer J; 2007; 13(5):327-34. PubMed ID: 17921732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients].
    Laatiri MA; Elloumi M; Ali ZB; Ben Othmen T; Msadek F; Toumi N; Bouaouina N; Daoud J; Maalej M; Ghannem H; Meddeb B
    Bull Cancer; 2010 Apr; 97(4):409-16. PubMed ID: 20374978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.